Evaluation of the Birmingham IBS symptom questionnaire by Roalfe, Andrea K et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
Evaluation of the Birmingham IBS symptom questionnaire
Andrea K Roalfe*, Lesley M Roberts and Sue Wilson
Address: Department of Primary Care and General Practice, Division of Primary Care, Public and Occupational Health, University of Birmingham, 
Edgbaston, Birmingham, B15 2TT, UK
Email: Andrea K Roalfe* - a.k.roalfe@bham.ac.uk; Lesley M Roberts - l.m.roberts@bham.ac.uk; Sue Wilson - s.wilson@bham.ac.uk
* Corresponding author    
Abstract
Background:  Irritable Bowel Syndrome (IBS) is a chronic/common condition that causes a
significant effect on the individual (reduced quality of life), society (time lost off work) and health
services. Comparison of studies evaluating the management of IBS has been hindered by the lack
of a widely adopted validated symptom score. The aim of this study was to develop and validate a
disease specific score to measure the symptoms of patients with IBS.
Methods: A self-administered 14-item symptom questionnaire (based on Rome II criteria) was
mailed to 533 persons included in a prevalence study of IBS. The reliability of each underlying
dimension identified was measured by Cronbach's α. Validity was assessed by comparing symptom
scores with concurrent IBS specific quality of life (QoL) scores. Reproducibility was measured by
the test-retest method and responsiveness measured by effect size.
Results: 379 (71%) questionnaires were returned. The underlying dimensions identified were pain,
diarrhoea and constipation. Cronbach's α was 0.74 for pain, 0.90 for diarrhoea and 0.79 for
constipation. Pain and diarrhoea dimensions had good external validity (r = -0.3 to -0.6),
constipation dimension had moderate external validity (r = -0.2 to -0.3). All dimensions were
reproducible (ICCs 0.75 to 0.81). Effect sizes of 0.27 to 0.53 were calculated for those with a
reported improvement in symptoms.
Conclusion: The Birmingham IBS Symptom Questionnaire has been developed and tested. It has
been shown to be suitable for self-completion and acceptable to patients. The questionnaire has 3
internal dimensions which have good reliability, external validity and are responsive to a change in
health status.
Background
Irritable Bowel Syndrome (IBS) affects large numbers of
the population (prevalence estimates ranging from 12%
to 30%) [1-7] and accounts for a significant proportion of
the workload of both primary care practitioners and gas-
troenterologists [8]. Treatment options are wide ranging
and include symptomatic prescribing, dietary manage-
ment and a range of psychotherapeutic and complemen-
tary therapies. The breadth of the problem and the range
of treatment options make this a potential area for much
research activity.
The diversity of symptom types and profiles in IBS means
that there is no agreement on appropriate determination
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of efficacy in trials. Researchers have therefore used a
range of techniques and measures, which are largely arbi-
trary and unvalidated.
Three large systematic reviews completed in the UK,
Europe and the USA [9-11] demonstrated large variety in
the primary outcome measures adopted by trialists, with
many trials reporting individual symptoms, such as pain
or urgency or more arbitrary outcomes such as percentage
of unformed stools. A review of randomised controlled
trials of pharmacological treatments [12], noted that
symptom data were most commonly collected by daily
diary (56% of trials), or during consultation. Only 4/70
included trials reported use of a symptom questionnaire
and only 2 of these reported validation of the chosen
measure [13,14].
Selection of a suitable outcome measure is further compli-
cated by the fluctuating nature of IBS. It has been sug-
gested [15], that due to the variance of symptoms over
time, clinical trials in this area should have a minimum
duration of 2–3 months. The increase in psychotherapeu-
tic and complementary therapies such as hypnotherapy
for the management of IBS, would suggest that follow-up
should be even longer, as such therapies may prove to be
effective (and cost-effective) over extended periods by
dealing with root causes or the learning of self-manage-
ment techniques. The use of daily diary data collection
strategies over long periods may be unfeasible or may
increase drop-out rates leading to a biased sample.
The ROME I, II and III trial committees have consistently
agreed that the main assessment of outcome in IBS trials
should be patient centred [16-18] and over a decade ago
Tally et al [17], strongly proposed the need to develop
sensitive outcome measures with multiple domains as a
priority in this area. A recent move towards global assess-
ment, led to the adoption of 'adequate relief' as a primary
endpoint in some trials [19-21] and a literature review of
outcome measures identified a dichotomous 'adequate
relief' question as the measure of first choice in assessing
global symptomatology [22]. The ROME III committee
now indicate that 'adequate' or 'satisfactory' relief are the
current standards for primary outcome assessment in
treatment trials in IBS [18] and this was supported by a
recent review of primary endpoints in IBS trials [23]. It is
however generally indicated that integrative symptom
questionnaires are also acceptable endpoints subject to
appropriate validation [18].
There is the risk that exclusive use of dichotomous or 'ade-
quate relief' endpoints in a disease with such differing
symptom profiles may result in the failure to identify ther-
apies of benefit to sub-groups of patients or effective on
specific symptoms. The GSRS-IBS symptom score [24],
based on Rome I criteria has been shown to discriminate
by severity and frequency of disease symptoms. However
this tool has not been widely used in practice and its gen-
eralisability across all age groups has yet to be demon-
strated. A recent visual analogue scale for IBS (VAS-IBS)
has been developed [25], however this tool was validated
on a sample of women only and requires further testing in
clinical practice to establish responsiveness.
Therefore the continuing need for a symptom measure
suitable for use in a range of clinical and management tri-
als in the area of IBS remains. The principle characteristics
of this tool were determined to be 1) patient reported, 2)
suitable for repeated testing over extended time periods,
3) acceptable to patients for ongoing completion, and 4)
containing multiple dimensions covering relevant symp-
toms. This paper therefore describes the development and
validation of a tool which meets these requirements, is
suitable for self-completion and postal return and fulfils
the recommendations of the ROME working group
regarding validation of a primary outcome measure [16].
Identification of a well validated and increasingly adopted
IBS specific quality of life measure [26,27], limited the
development of this new tool to a symptom only score
which would be used to complement this.
The aim of this study was to develop a symptom score
suitable for use in a range of therapeutic trials in IBS and
establish its acceptability, reliability, validity and sensitiv-
ity to a change in health.
Methods
Ethics
Ethical approval for the study, in which this symptom
score validation was embedded, was obtained from North
and West Birmingham Local Research Ethics Committees
before commencement of the project.
Population
A computer generated random sample (stratified by dep-
rivation quartile) of 8646 patients, aged 18 and over, reg-
istered with participating practices, were mailed in a study
estimating the prevalence of IBS in the West Midlands
[28]. This mailing contained a general health question-
naire which asked about previous diagnosis of IBS and
also questions based on the ROME II [29], diagnostic cri-
teria for IBS. Five hundred and thirty three people were
identified who met the Rome II criteria (n = 398) or who
had an existing diagnosis of IBS with some current symp-
toms or the need for medication during the last 6 months
(n = 135). This population formed the target population
for the validation of the IBS-specific symptom score.
Patients with other pre-existing GI conditions were
excluded.BMC Gastroenterology 2008, 8:30 http://www.biomedcentral.com/1471-230X/8/30
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The Birmingham IBS symptom score
The Birmingham IBS symptom score comprised a self-
completed questionnaire which consisted of 14 questions
based on the frequency of IBS related symptoms and was
derived from Rome II: Functional intestinal disorders (see
Additional file 1). Each question had a standard response
scale with symptoms all being measured on a 6-point Lik-
ert scale ranging from 0 = none of the time to 5 = all of the
time. Several authors have suggested measuring symptoms
with visual analogue scales (VAS) [30,31], however there
is no firm evidence of the superiority of VAS over Likert
scales [32,33], therefore the latter were adopted as they
were felt to be more familiar to patients and also less
labour intensive to analyse.
Validation
The Birmingham IBS symptom score was sent to persons
within 1 to 2 working days of their response to the Gen-
eral Health Questionnaire, which identified them as eligi-
ble. To examine construct validity, participants were also
sent the IBS-QOL [26], a previously validated disease spe-
cific quality of life measure. A freepost envelope was sup-
plied for the return of questionnaires. Individuals who
did not return a questionnaire within 21 days were re-
mailed on one occasion.
Seven days after the return of the Birmingham IBS symp-
tom questionnaire the participants were sent a repeat
symptom questionnaire which was identical except for the
addition of a single question to provide data on change of
disease status. This asked about changes between com-
pleting the first and second symptom score (Since complet-
ing the last questionnaire my abdominal and bowel symptoms
have improved/got worse/remained the same). At the time of
completing the first questionnaire participants were una-
ware that they would be asked to repeat the score. Respon-
siveness to change was assessed by these data and
reproducibility was determined by data relating to per-
sons who reported no change in symptoms.
Analysis
Acceptability was explored by consideration of the overall
response rate (percentage of questionnaires returned) and
the completeness of each question (proportion of each
individual question with a valid response).
The percentages of subjects selecting either the lowest
response (floor) or highest response (ceiling) for each
question were examined to evaluate floor and ceiling
effects, because a large ceiling or floor effect would limit
the ability of the questionnaire to detect change over time.
Factor analysis with varimax rotation was carried out to
identify underlying dimensions within the questionnaire.
The number of dimensions was determined with Scree
plots and eigenvalues (> 1). The items within each dimen-
sion were confirmed by a cross-validation analysis,
whereby questionnaires were randomly allocated into
two subgroups of equal size and factor analysis repeated
on each subgroup. To allow comparison with other symp-
tom scores, the items within each dimension were
summed and transformed to a scale ranging from 0 (no
symptoms) to 100 (all symptoms).
The reliability of each identified dimension was assessed
by examination of internal consistency and reproducibil-
ity. Internal consistency was measured by Cronbach's α
coefficient [34]. Reproducibility was assessed using data
from the second mailing (test-retest) and measured with
the intra-class correlation coefficient (ICC). The ICC was
obtained from analysis of variance [35] and identifies
how much variation in scores is due to true difference
between individuals and how much is attributable to var-
iability in the measurement.
Construct validity, assessing whether dimensions measure
what they say they do, was examined by the relationship
of persons' symptom dimension scores with their QoL
scores. The associations were measured using Spearman's
rank correlation coefficients.
The responsiveness of the tool was measured by the effect
size [36,37], for reported changes in symptoms between
the first and second mailings. Effect size for each dimen-
sion and total score was calculated from the mean change
in scores between first and second mailing divided by the
standard deviation of scores at baseline.
Results
Demography
The questionnaire was mailed to 533 persons. The average
age was 50 years (range 18–89); 73% were female (mean
age 49 years) and 27% male (mean age 54 years). Eighty-
eight percent of the sample was white and 59% had left
school by age 16. Thirty-nine percent were in full-time
employment; 9% worked part-time; 24% retired, 15%
unable to work for health reasons and 3% were unem-
ployed.
Acceptability
379 (71%) of the 533 eligible population returned the ini-
tial Birmingham IBS symptom score questionnaire. The
age, sex, ethnicity, education and employment status dis-
tributions of the responders were similar to the non-
responders.
Individual item completion rates were all very high and
ranged from 97.6% to 99.7%. No individual item demon-
strated a substantial floor or ceiling effect, all extreme
responses being selected by less than 80% of respondentsBMC Gastroenterology 2008, 8:30 http://www.biomedcentral.com/1471-230X/8/30
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(Table 1) and therefore no questions were rejected on
these grounds. The items with the highest response to a
single category were leaked or soiled and mucus or slime
where 74% and 57% respectively gave the response of
'none of the time'.
Underlying Dimensions
Factor analysis with varimax rotation identified 3 under-
lying dimensions within the score. Three questions
(12,13,14) however produced inconsistent factor load-
ings when compared with a cross-validation analysis. This
suggested that these questions were unreliable and they
were therefore excluded from further analysis. The 3
dimensions could best be described as relating to consti-
pation (3 items), diarrhoea (5 items) and pain (3 items),
explaining 26%, 22% and 20% of the variation respec-
tively (Table 2). An overall IBS symptom score was also
calculated by the summation of the final 11 questions.
Internal consistency
Cronbach's α coefficients were 0.79 for constipation, 0.90
for diarrhoea, 0.74 for pain and 0.75 for overall score.
Reproducibility
329/379 (87%) questionnaires were returned from the
repeat mailing to those who returned symptom scores.
Seventy-five percent (248) patients reported no change in
symptoms over the 7–10 day period since completion of
the initial score. The ICCs calculated were 0.78 for consti-
pation, 0.81 for diarrhoea, 0.75 for pain and 0.78 for over-
all score.
Validity
A negative association was found between each symptom
dimension and the previously validated IBS-QoL dimen-
sions (i.e. quality of life increased as symptoms
decreased). Spearman's correlation coefficients between
each scale and symptom scores ranged between -0.1 to -
0.3 for constipation; -0.3 to -0.5 for diarrhoea; -0.4 and -
Table 1: Question completion rates and maximum response frequencies
Question Number completed % completed Maximum % response at extremes
Pain 377 99.5 6.1
Loose, watery stools 377 99.5 28.7
Diarrhoea 376 99.2 44.4
Hard bowel motions 374 98.7 22.2
Straining 375 98.9 20.0
Constipation 376 99.2 35.6
Pain after eating 378 99.7 20.4
Sleep problem 377 99.5 36.9
Leaked or soiled 375 98.9 73.9
Urgency 377 99.5 21.5
Mucus or slime 370 97.6 56.8
Unfinished bowel movement 375 98.9 7.7
Flatulence 378 99.7 7.9
Back and shoulder pain 370 97.6 46.8
Table 2: Factor coefficients after varimax rotation
Question Factor1 Factor2 Factor3 Factor description
Hard bowel motions 0.90 Constipation
Straining 0.86
Constipation 0.89
Loose, watery stools 0.59
Diarrhoea 0.63
Leaked or soiled 0.76 Diarrhoea
Urgency 0.66
Mucus or slime 0.70
Pain 0.78
Pain after eating 0.84 Pain
Sleep problem 0.65
Eigenvalue 2.8 2.4 2.2BMC Gastroenterology 2008, 8:30 http://www.biomedcentral.com/1471-230X/8/30
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0.6 for pain. Overall scores ranged from -0.5 to -0.7 (Table
3).
Responsiveness
Mean scores increased for those reporting worse symp-
toms at the second mailing overall and across pain and
diarrhoea dimensions. Conversely the mean scores
decreased overall and across all 3 dimensions for all those
reporting an improvement in symptoms. Small effect sizes
were found for those who reported worse symptoms over-
all and across all dimensions (0.06 to 0.18); a similar
degree of responsiveness was found for those with no
reported change in symptoms (0.06 to 0.13). Of those
with a reported improvement, medium effect sizes (0.46,
0.53) were identified for the pain dimension and overall
scores; and small effect sizes (0.27, 0.32) for the constipa-
tion and diarrhoea dimensions (Table 4).
The final Birmingham IBS symptom questionnaire is
shown in the attached file (see Additional file 2).
Discussion
Unlike other symptom scores validated using referral-
based populations, the validation of this questionnaire
was carried out on a large representative community
based cohort. Our primary aim was to create a patient
reported score for repeated use in trials – in this setting
patient interpretation of symptoms is not an issue and
could be beneficial, allowing patients to self-define symp-
toms within tight parameters. Translation to a clinical set-
ting will require further testing especially in light of
known differences in the way patients and doctors define
key symptoms such as constipation [38].
The high response rate and the high completion rates of
all questions demonstrate the questionnaire's acceptabil-
ity and suitability for self-completion. The possibility of a
response bias due to 15% of responders not working
because of health problems may exist. However the prev-
alence of a range of conditions such as diabetes (5%),
hypertension (31%) and cancer (4%) are similar to UK
figures and thus our responders reflect the general mor-
bidity of a community population. Patients with other
pre-existing GI conditions were excluded from the study.
Three underlying dimensions were identified within the
questionnaire with Cronbach's alpha coefficients of
between 0.7 and 0.9. These are consistent with recom-
mendations of internal reliability [34,39,40] and provide
evidence that the items within each dimension are meas-
uring the same characteristic.
The stability of the responses was demonstrated by the
high intra-class correlation coefficients of between 0.75
and 0.81. Consequently we can be confident that changes
Table 3: Construct validity measured by Spearman correlation 
coefficients
Symptom dimension
QoL dimension Constipation Diarrhoea Pain Overall
Dysphoria -0.2 -0.5 -0.6 -0.6
Body image -0.3 -0.4 -0.6 -0.7
Health worry -0.3 -0.4 -0.5 -0.6
Food avoidance -0.1 -0.4 -0.5 -0.5
Social reaction -0.2 -0.5 -0.5 -0.6
Sexual -0.2 -0.3 -0.4 -0.5
Relationships -0.2 -0.3 -0.4 -0.5
Overall QoL -0.2 -0.5 -0.6 -0.7
Table 4: Responsiveness measured by effect size
Dimension Health status at 7/10 days Baseline Change at 7/10 days Effect size
Mean (SD) Mean (SD)
Pain
Worse (n = 30) 38.2 (21.7) 3.8 (21.6) 0.18
Same (n = 245) 33.3 (19.2) -2.4 (12.5) 0.13
Improved (n = 47) 31.0 (22.1) -10.2 (14.4) 0.46
Constipation
Worse (n = 30) 25.8 (22.0) -1.3 (16.5) 0.06
Same (n = 242) 35.0 (27.7) -1.6 (16.4) 0.06
Improved (n = 48) 32.2 (25.2) -6.8 (15.9) 0.27
Diarrhoea
Worse (n = 29) 31.2 (24.7) 3.9 (10.7) 0.16
Same (n = 236) 21.1 (16.9) -1.4 (10.0) 0.08
Improved (n = 46) 19.4 (17.0) -5.4 (11.8) 0.32
Overall
Worse (n = 29) 31.6 (16.8) 2.3 (10.6) 0.14
Same (n = 230) 28.2 (13.3) -1.6 (8.2) 0.12
Improved (n = 46) 26.1 (14.0) -7.4 (9.5) 0.53BMC Gastroenterology 2008, 8:30 http://www.biomedcentral.com/1471-230X/8/30
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measured by this tool will be due to the effect of treatment
and not due to measurement errors of the tool.
Increases in pain, diarrhoea and constipation scores were
associated with decreasing quality of life confirming con-
struct validity thus providing evidence that they measure
what they purport to. As anticipated, the Qol scores corre-
lated more highly with the pain scale [26].
The decrease in all scores, and corresponding small to
medium effect sizes following an improvement in symp-
toms, indicate the tool's sensitivity to detect a change in
health. The small effect sizes found for those with worse
symptoms are most probably due to a ceiling or regression
to the mean effect. In these cases, baseline scores, with the
exception of constipation, were from subjects with greater
symptoms than an average IBS sufferer and therefore
scores were unlikely to increase. These changes were
observed after a short duration of time (7–10 days); how-
ever differences at 3 months have also been shown. A ran-
domised controlled trial of gut-directed hypnotherapy
demonstrated an improvement in the Birmingham IBS
pain, diarrhoea and overall symptom scores at 3 months
compared to usual management [41]. An ongoing ran-
domised controlled trial of a dietary product will provide
further estimates of responsiveness over time to supple-
ment these results.
The questionnaire performed well for both genders with
similar results for reliability, validity and reproducibility
being found for men and women. However, gender spe-
cific effect sizes could not be reliably estimated due to the
small sample of males reporting a change in symptoms.
Whilst the instrument meets validation criteria, it is
acknowledged that it may not query the full and diverse
range of symptoms experienced by IBS sufferers. The
inclusion of additional questions, or the opportunity for
patient nomination of personal outcomes (as in MYMOP
[42]), may further enhance the tool.
Conclusion
This IBS specific symptom questionnaire has been appro-
priately developed and tested. It is patient-centred, suita-
ble for self-completion and is acceptable. The score
includes multiple dimensions that cover representative
and relevant questions. The dimension and summary
scores provide reliable and valid outcome measures of IBS
symptoms. High levels of reproducibility indicate that the
score is suitable for use in therapeutic trials where it is
important to establish that measured changes reflect a real
change in status, not just variability in measurement. The
increase in effect size, with improvement in symptoms
confirms the instrument's ability to measure a clinically
meaningful change in health. It is particularly important
that a symptom questionnaire is responsive to a change in
health if it is to be used as an outcome in a clinical trial.
The severity of symptoms experienced by populations
recruited to treatment trials should be reported if general-
isability is to be established. The lack of an acceptable and
validated disease specific symptom score has hampered
the comparison of the efficacy of different management
strategies or attempts to synthesise the results of existing
studies in the area of IBS. We recommend that future stud-
ies of IBS utilise the Birmingham IBS symptom score,
together with the previously well validated IBS-QoL ques-
tionnaire, to facilitate the production of high quality
patient centred research and to enable future comparisons
between published studies and meta-analysis of data.
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